Case report Plasmablastic Lymphoma Plasmablastic Lymphoma-Rare tumour in an Uncommon Site: A Case report (original) (raw)
Related papers
2018
Plasmablastic lymphoma (PBL) was first described in the jaws and the oral cavity of human immunodeficiency virus infected patients. This subtype of lymphoma is considered as a variant of the diffuse large B-cell lymphoma with a phenotype of plasma cell differentiation that expresses markers such as CD38, CD138 and MUM1 protein. HIV-associated PBL is associated with an aggressive clinical course, poor prognosis and shot survival even in the era of highly active antiretroviral therapy (HAART). Primary soft tissue Non-Hodgkin lymphomas (NHL) are very rare and account only the 0.1% of the cases. Generally, NHL of the soft tissue present as large subcutaneous masses, with fast growing and without evidence of nodal or skin involvement. Here we describe a primary NHL of the soft tissue in an HIV infected patient. Abstract Figure 1. A large right cervical-thoracic mass.
2018
Plasmablastic lymphoma (PBL) was first described in the jaws and the oral cavity of human immunodeficiency virus infected patients. This subtype of lymphoma is considered as a variant of the diffuse large B-cell lymphoma with a phenotype of plasma cell differentiation that expresses markers such as CD38, CD138 and MUM1 protein. HIV- associated PBL is associated with an aggressive clinical course, poor prognosis and shot survival even in the era of highly active antiretroviral therapy (HAART). Primary soft tissue Non-Hodgkin lymphomas (NHL) are very rare and account only the 0.1% of the cases. Generally, NHL of the soft tissue present as large subcutaneous masses, with fast growing and without evidence of nodal or skin involvement. Here we describe a primary NHL of the soft tissue in an HIV infected patient.
Large abdominal mass as clinical presentation of plasmablastic lymphoma
Clinical Microbiology and Infectious Diseases, 2016
Plasmablastic lymphoma (PBL), a very aggressive variant of diffuse large B cell lymphoma (DLBCL), has been described initially as a rapidly progressive and almost invariably fatal diffuse large-cell lymphoma with plasmablastic features. Immunohistochemical findings showed generally CD20 antigen negative and VS38c, CD138 and MUM 1 positives. This neoplasm was initially described almost exclusively involving the jaw and oral mucosa in HIV-positive patients. However, most recently, the clinical spectrum of the disease has been expanding, with a number of single case reports in HIV-negative patients and with extra-oral manifestations.
Plasmablastic lymphoma presenting in a human immunodeficiency virus-negative patient: a case report
Annals of Hematology, 2003
Plasmablastic lymphoma (PBL), an aggressive non-Hodgkin's lymphoma that carries a poor prognosis, previously has been identified almost exclusively in patients infected with the human immunodeficiency virus (HIV). We present a case of a 42-year-old HIV-negative patient presenting with an isolated nasal cavity mass, the typical presentation for PBL. The patient was given systemic chemotherapy, central nervous system prophylaxis, and consolidative locoregional radiotherapy and achieved a complete clinical response. This case suggests PBL should be considered in HIV-negative patients with characteristic findings.
Tibial Plasmablastic Lymphoma in a HIV-Negative Child: A Novel Extraoral Localisation
Case reports in hematology, 2022
Plasmablastic lymphoma is an aggressive, high-grade non-Hodgkin lymphoma predominantly seen in HIV-infected individuals. Alongside a strong correlation with HIV, PBL can manifest in immunocompromised HIV-negative patients. A rare case of PBL in an immunocompetent and otherwise healthy child presented to Indus Hospital & Health Network (IHHN), Karachi, Pakistan. e patient had complaints of swelling and pain in the right leg and was referred from a city in Interior Sindh. Histopathological analysis revealed sheets and aggregates of neoplasm replacing bone marrow interspersed with sclerotic bony fragments. Large, monomorphic, multinucleated neoplastic cells containing abundant cytoplasm and scattered pleomorphic cells were also noted, leading to the diagnosis of tibial plasmablastic lymphoma. A FAB/LMB96 group C chemotherapy regimen for aggressive and high-risk cancer was administered with a marked improvement in clinical symptoms.
Clinical Oncology, 1998
A patient with human immunodeficiency virusrelated non-Hodgkin's lymphoma arising in the oral cavity is reported. The tumour had an unusual immunohistochemical profile that was negative for leucocyte common antigen and the B-cell antigen CD20 but positive for the plasma cell-reactive antibody VS38c. The features of this type of turnout, which has recently been categorized, are presented and discussed.
Plasmablastic Lymphoma: A Systematic Review
The Scientific World JOURNAL, 2011
represents a diagnostic challenge given its characteristic morphology and lack of CD20 expression, and also a therapeutic challenge, with early responses to therapy, but with high relapse rates and poor prognosis. In recent years, our understanding and clinical experience with PBL has increased in both HIV-positive and -negative settings. However, given its rarity, most of the data available rely on case reports and case series. The main goal of this article is to systematically review the most recent advances in epidemiology; pathophysiology; clinical, pathologic, and molecular characteristics; therapy; and prognosis in patients with PBL. Specific covered topics include new pathological markers for diagnosis, its association with Epstein-Barr virus, and the need of more intensive therapies.
South Asian Journal of Cancer
Background Plasmablastic lymphoma (PBL) is a rare aggressive B cell lymphoma that is commonly encountered in patients with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). In this case series, we describe the clinicopathological features of cases of PBL seen at a tertiary care center in South India. Materials and Methods Medical records of patients diagnosed with PBL between January 2009 and November 2017 were reviewed. PBL was defined as per the World Health Organization 2016 classification for hematopoietic and lymphoid neoplasms. The slides were reviewed with hematoxylin and eosin along with immunohistochemistry (IHC) including CD45, CD20, PAX5, CD79a, CD3, CD5, CD138, MUMI, EMA, ALK, and Ki67. Epstein-Barr virus (EBV) association was documented by rapid in situ hybridization (RISH) studies wherever possible. The demographic data, clinical presentation, treatment details, and outcomes are elaborated using descriptive statistics. Results During the stu...
Plasmablastic Lymphoma: A Challenging Diagnosis
2020
Introduction: Plasmablastic lymphoma (PBL) is an aggressive lymphoma characterized by early relapses and subsequent chemotherapy resistance representing therefore diagnostic and therapeutic challenge with a very poor outcome. Case Presentation: A 53-year-oldfemale patient presented with dyspnea and general status alteration due to anemia; diagnosed as hemolytic anemia and treated by corticotherapy without amelioration. The most recent hospitalization revealed worsening of her symptoms with weight loss of 5 kilos in one week, anorexia and lumbar pain. Physical examination showed isolated splenomegaly with no signs of bleeding, adenopathy nor a palpable breast mass. Extended laboratory tests were normal, except normocytic anemia with hemoglobin =8.76 g/dl; hct=26.6%; MCV=89.2 fl and a low haptoglobin concentration level <0.04 g/l with a high value of LDH 1165 UI/litre. Hypercalcemia of 12 mg/dl was also noted with low PTH. To complete the workup: imaging showed a total body CT scan...